Compare PRPL & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPL | VTGN |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.8M | 122.1M |
| IPO Year | N/A | N/A |
| Metric | PRPL | VTGN |
|---|---|---|
| Price | $0.77 | $0.74 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $1.00 | $0.90 |
| AVG Volume (30 Days) | 273.1K | ★ 5.4M |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $457,012,000.00 | $721,000.00 |
| Revenue This Year | N/A | $54.26 |
| Revenue Next Year | $12.69 | $478.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $0.68 |
| 52 Week High | $1.29 | $5.14 |
| Indicator | PRPL | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 22.93 |
| Support Level | $0.73 | $3.91 |
| Resistance Level | $0.80 | $4.50 |
| Average True Range (ATR) | 0.05 | 0.38 |
| MACD | -0.00 | -0.43 |
| Stochastic Oscillator | 19.30 | 2.49 |
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.